ERBB2 and breast carcinoma: For premenopausal female patients with HR‐positive/HER2‐negative advanced breast cancer, alpelisib in combination with endocrine therapy has been shown in the B‐YOND study [37] to be a potentially effective regimen (with a median PFS of 25.2 months and an ORR of 50.0%).